ArticleActa cirurgica brasileira2025
Peripheral nerve injury recovery enhanced by ceftriaxone: a preclinical investigation.
Article in Acta cirurgica brasileira, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate ceftriaxone's potential in enhancing peripheral nerve injuries (PNIs) recovery.
methodsThirty male Wistar rats were divided into control (no surgery), vehicle (sciatic nerve injury + 0.9% NaCl), and ceftriaxone (sciatic nerve injury + 50 mg/kg/day ceftriaxone) groups. Treatments were administered intraperitoneally for 12 weeks. Functional recovery was assessed using inclined plane tests and electromyography. Sciatic nerve regeneration was evaluated via histology, nerve growth factor (NGF) immunohistochemistry, and enzyme-linked immunosorbent assay.
resultsCompared to the control group, inclined plane test scores, nerve action potentials, NGF expression, axon counts, and diameters were diminished in both injury groups (p 0.001). However, these parameters were significantly improved in the ceftriaxone group compared to the vehicle group (p 0.001). Increased fibrosis was observed in the ceftriaxone group.
conclusionCeftriaxone demonstrates potential as a pharmacological agent for PNI recovery by enhancing nerve regeneration and functional outcomes. Further studies are warranted to elucidate its mechanisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.